Literature DB >> 7714484

GACPAT HIV 1 + 2: a simple, inexpensive assay to screen for, and discriminate between, anti-HIV 1 and anti-HIV 2.

J V Parry1, J A Connell, P Reinbott, A B Garcia, F Avillez, P P Mortimer.   

Abstract

A simple and cheap assay suitable for screening for anti-HIV 1 and anti-HIV 2 and discriminating between them was evaluated. In it specimens are incubated in U-bottomed microplate wells coated with anti-human IgG for 30 min at room temperature. After washing, 100 microliters of a 1 in 50 dilution of HIV 1-coated gelatin particles (Serodia-HIV 1/2, Fujirebio) are added. Settling patterns are read on the second day: A positive reaction is indicated by adherence of the particles and a negative by a button. The HIV 1 particles are then washed away and HIV 2 particles added. Anti-HIV 2 reaction patterns are read on the third day. To assess the performance of the modified "GACPAT HIV 1 + 2" assay a panel of 1,621 serum/plasma specimens was used. It comprised validated anti-HIV 1 positive (n = 220), anti-HIV 2 positive (n = 214), dual anti-HIV 1/anti-HIV 2 positive (n = 11), and anti-HIV negative (n = 1,176) serum/plasma specimens. All 434 specimens that contained anti-HIV 1 or anti-HIV 2 reacted positively with the homologous particles. The 11 dually positive specimens reacted positively with both HIV 1 and HIV 2 particles. Five (2.3%) anti-HIV 1 and five (2.3%) anti-HIV 2 positive specimens gave positive reactions with both particle types, but none of the five cross-reactive anti-HIV 2 specimens were dually reactive when the order of particle addition was reversed.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7714484     DOI: 10.1002/jmv.1890450103

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  5 in total

1.  Tuberculosis in England and Wales in 1993: results of a national survey. Public Health Laboratory Service/British Thoracic Society/Department of Health Collaborative Group.

Authors:  D Kumar; J M Watson; A Charlett; S Nicholas; J H Darbyshire
Journal:  Thorax       Date:  1997-12       Impact factor: 9.139

2.  Performance of the Amplicor human immunodeficiency virus type 1 PCR and analysis of specimens with false-negative results.

Authors:  K L Barlow; J H Tosswill; J V Parry; J P Clewley
Journal:  J Clin Microbiol       Date:  1997-11       Impact factor: 5.948

3.  High-prevalence and high-estimated incidence of HIV infection among new injecting drug users in Estonia: need for large scale prevention programs.

Authors:  Anneli Uusküla; Mart Kals; Kristiina Rajaleid; Katri Abel; Ave Talu; Kristi Rüütel; Lucy Platt; Tim Rhodes; Jack Dehovitz; Don Des Jarlais
Journal:  J Public Health (Oxf)       Date:  2008-02-28       Impact factor: 2.341

4.  Expanded syringe exchange programs and reduced HIV infection among new injection drug users in Tallinn, Estonia.

Authors:  Anneli Uusküla; Don C Des Jarlais; Mart Kals; Kristi Rüütel; Katri Abel-Ollo; Ave Talu; Igor Sobolev
Journal:  BMC Public Health       Date:  2011-06-30       Impact factor: 3.295

5.  Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal).

Authors:  Pam Sonnenberg; Soazig Clifton; Simon Beddows; Nigel Field; Kate Soldan; Clare Tanton; Catherine H Mercer; Filomeno Coelho da Silva; Sarah Alexander; Andrew J Copas; Andrew Phelps; Bob Erens; Philip Prah; Wendy Macdowall; Kaye Wellings; Catherine A Ison; Anne M Johnson
Journal:  Lancet       Date:  2013-11-26       Impact factor: 79.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.